LA JOLLA, Calif. , Nov. 18, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will
Receipt of Final Reports from the Chronic Toxicity Studies for Submission of Complete Response to Reinitiate the Multiple Ascending Dose Clinical Study for RGLS4326 Appointment of Cris Calsada as New Chief Financial Officer LA JOLLA, Calif. , Nov. 12, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.
LA JOLLA, Calif. , Oct. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS) , a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs , today announced that it presented preclinical data that identifies RGLS4326, a
LA JOLLA, Calif. , Sept. 12, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Nature Communications has published an article entitled, "Discovery
LA JOLLA, Calif. , Sept. 3, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will
LA JOLLA, Calif. , Aug. 29, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will
Closing of First Tranche of $41.8 Million Private Placement of Equity Term Loan Restructured Providing Up to Two Years of Interest Only and Extended Maturity Date to May 2022 Data Requirements Defined to Reinitiate Multiple Ascending Dose and Chronic Dose Studies with RGLS4326 Appointment of Cris
LA JOLLA, Calif. , July 30, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the appointment of Cris Calsada as its new Chief Financial Officer effective
Data Requirements Defined To Reinitiate Multiple Ascending Dose And Chronic Dose Studies With RGLS4326 Single Ascending Dose Studies With RGLS4326 May Be Pursued LA JOLLA, Calif. , July 23, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the
LA JOLLA, Calif. , June 11, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced Jake Nunn and Simos Simeonidis , Ph.D.
